Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.65 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12148858 | 0.91 | EPHX2 (0.63) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12522320 | 0.91 | EPHX2 (0.63) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12087729 | 0.90 | EPHX2 (0.62) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL1866485 | 0.90 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL20687033 | 0.90 | EPHX2 (0.62) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12087758 | 0.90 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12148896 | 0.90 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL1866483 | 0.90 | SLC6A5 (0.64) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12087759 | 0.88 | EPHX2 (0.61) | EPHX2SLC6A5LPAR3LPAR1CNR1 | |
| SCHEMBL12514075 | 0.88 | EPHX2 (0.61) | EPHX2SLC6A5LPAR3LPAR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | SLC27A2, LYPLA2, SLC27A1 | EPHX2 3723/4885SLC6A5 602/4885LPAR3 588/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | EPHX2 3928/4885SLC6A5 890/4885LPAR3 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.